The drug has brought in billions of dollars for Otsuka and Bristol-Myers Squibb. The FDA reported that approximately 1.6 million people received a prescription for aripiprazole from a retail pharmacy in 2015. Over the course of its more than 15 years on the market, Abilify has been prescribed to millions of people. This allowed the drug to be administered to patients between 6 and 17 for aggression toward others, self-injury, uncontrollable tantrums, and mercurial moods, according to Reuters 2. In November 2009, Abilify was approved to treat irritability in children with autism. That same month, the FDA approved Abilify to treat schizophrenia in teens 1В between 13 and 17 years old. In 2007, its use was further expanded to include treatment for major depressive disorder 1В when used in conjunction with antidepressants. Two years later, the drug was approved for treatment of acute manic and mixed episodes associated with bipolar disorder.

Food and Drug Administration (FDA) in November 2002. Abilify was first approved for use in the treatment of schizophrenia in adults by the U.S. The company later partnered with Bristol-Myers Squibb to finish the drug, get approvals for use, and market the drug. It was first discovered by scientists working for Otsuka Pharmaceutical in the 1990s. Abilify, also known by its generic name aripiprazole, is a medication used to treat psychotic conditions, such as schizophrenia and bipolar disorder.

Ambify spotify